


### Financial disclosures





- ▶ No commercial conflicts of interest
- ► Consultant for IDEAYA Biosciences
- Support by
  - Leonard and Mary Lou Hoeft Career Development Award Fund in Ophthalmology Research
  - ► Grant Number P30 CA015083 from the National Cancer Institute
  - CTSA Grant Number KL2 TR002379 from the National Center for Advancing Translational Science (NCATS)
  - Contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

### **Objectives**

- ▶ Recognize key ocular tumors
- ▶ Understand how ocular tumors can impact visual acuity
- ▶ Understand how ocular tumors can impact survival









## Ocular Surface Tumors The Pigment Spectrum Conjunctival nevus Complexion-associated melanosis (CAM) Primary acquired melanosis (PAM) Malignant melanoma

## Conjunctival Nevus > Well-circumscribed > Pigmented 85% > Amelanotic 15% > Pseudocysts 65% > Not pathognomonic (lymphanglectasia, mucoepidermoid SCC)









## Ocular Surface Tumors The Pigment Spectrum Conjunctival nevus Complexion-associated melanosis (CAM) Primary acquired melanosis (PAM) Malignant melanoma

# Complexion-Associated Melanosis (CAM) Bilateral Symmetric Filat Often at the limbus Microfolds create cobblestone appearance More common with darker complexion Can extend to fornix, rare to tarsus





Ocular
Surface
Tumors

Complexion-associated melanosis
(CAM)

Primary acquired melanosis (PAM)

Malignant melanoma

Ocular
Surface
Tumors

The Pigment
Spectrum

Conjunctival nevus

Complexion-associated melanosis (CAM)

Primary acquired melanosis (PAM)

Malignant melanoma

### Primary Acquired Melanosis (PAM) Middle age Light complexion Unilateral, asymmetric Flat, peppery

► No cysts, cobblestone, or microfolds

Risk for melanoma



Ocular
Surface
Tumors

The Pigment
Spectrum

Conjunctival nevus

Complexion-associated melanosis (CAM)

Primary acquired melanosis (PAM)

Malignant melanoma

Ocular
Surface
Tumors

The Pigment
Spectrum

Conjunctival nevus

Complexion-associated melanosis (CAM)


Primary acquired melanosis (PAM)


Malignant melanoma

### Malignant Melanoma

- ▶ Pigmented (but not always!)
- Elevated
- Feeder and intrinsic vessel
- > 25% risk for metastasis at 10 years
- ▶ Medical oncology referral for systemic workup


















### What is this?

- ▶ Might have no pigment
- Can be subtle
- Always approach as if it could be melanoma




Treatment of Conjunctival Melanocytic Lesions

### **Treatment Options**

- SurgeryTopical Therapy
- Radiotherapy

### Surgery

- No touch technique
- ► Alcohol keratectomy
- Partial lamellar scleroconjunctivectomy
- > 2-4 mm margins
- Double freeze thaw cryotherapy
- ▶ First surgery is most important
- ▶ No BSS keep it off the field
- Clean instruments with alcohol if moving to a new location
- Use different, clean instruments for closure
- ► SLN if > 2mm thick




### **Topical Therapy**

- ► Mitomycin C (0.02-0.04%)
- Akylating agent
- ▶ For PAM
- Adjuvant for melanoma
- Wait 1-2 weeks after surgery
- ▶ Use for 7-28 days
- Side effects: keratoconjunctivitis, limbal stem cell deficiency
- Interferon alpha-2b (1 million IU/mL)
- ▶ Glycoprotein, acts at cell surface
- ▶ Adjuvant for PAM/melanoma
- Side effects: keratoconjunctivitis, less discomfort than MMC
- Less evidence than MMC


### Radiotherapy

- Plaque
- Adjuvant after excision ► Treats deep sclera
- Wait for healing after surgery
- ▶ 100 Gy, depth of 1-3 mm ▶ Side effects: dry eye, corneal ulcer
- ▶ Well tolerated
- ▶ EBRT/Proton beam
- ▶ Less commonly used
- ▶ For extensive disease
  - More recurrence More metastasis
- ▶ More radiation side effects
  - Dry eye, cataract, limbal stem cell deficiency
     Lash loss with proton









Ocular Surface Squamous Neoplasia (OSSN)

Ocular Surface **Tumors** The

Amelanotic

Ocular Surface Squamous Neoplasia (OSSN)

### Overview




- Most common amelanotic corneal and conjunctival malignancy Includes
- Dysplasia


  - ▶ Squamous cell carcinoma
  - Invades the basement membrane
- Local invasion uncommon but can occur


### **Demographics** Fair-skinned Middle-aged or older ▶ Immunosuppression/HIV if young Men>Women Sunlight exposure ► HPV **16, 18, 33** Smokers ▶ More bilateral


### Clinical Features

- Unilater
- ▶ Limbus
- ► Interpalpebral fissure
- Fornix, palpebral conjunctival less common
  - ▶ More in smokers
- Sessile or dome-shaped, gelatinous mass
- ▶ Feeder and intrinsic vessels
- Leukonlakia
- Can involve corneal epitheliu
- Amelanoti
  - Pigment common with pigmented complexion








































Treatment of OSSN	
-------------------	--

### Surgical Excision


- >50% recurrence if positive margins
  - 0-21% recurrence with current techniques







### Surgical Technique

- ▶ No touch technique
- ▶ Alcohol keratectomy
- ▶ Partial lamellar scleroconjunctive ctomy
- > 2-4 mm margins
- ▶ Double freeze thaw cryotherapy
- ► First surgery is most important
- No BSS keep it off the field
- ► Clean instruments with alcohol if moving to a new
- ▶ Use different, clean instruments for closure


















### **Topical Therapy**

- ▶ 5-fluorouracil (1%)
- ▶ Interferon alpha-2b (1 million IU/mL)
- ► Mitomycin C (0.02-0.04%)
- ▶ More time, more follow-up required
- ▶ Primary treatment, chemoreduction before surgery, or adjuvant after surgery
- ▶ Insurance coverage can be challenging


### 5FU


- Antimetabolite
- Interrupts DNA replication and cell growth
- ▶ 1% concentration
- 1 cycle: QID for 1 week, followed by 3 weeks of no medication
- ► Repeat until resolution
- ▶ 82-100% response rate
- ▶ 10-14% recurrence
- Side effects:
  - ▶ Pain
  - Tearing
  - Redness
  - Eyelid edemaKeratopathy
- Generally well-tolerated
- Compounded
- Low cost compared with others in US

### IFN Side effects: Glycoprotein Keratoconjunctivitis Acts at cell surface Flu-like symptoms with injection ▶ 1 million IU/mL Very well-tolerated ► Topical and subconjunctival use Compounded ▶ 10 MIU for subconj Expensive in US, less expensive in other countries Topical: QID until resolution, then continue for 1-3 additional months ► Subconj: once per month ▶ Difficult to obtain in US > 81-100% response rate ▶ 0-4% recurrence

### MMC

- Alkylating agent
- 0.02-0.04%
- ▶ 1 cycle: QID for 1 week on, 1 week off, 1 week on, 1 week off
  - Wait AT LEAST 1-2 weeks after surgery for healing
- Repeat until resolution76-100% response rate
- > 0-20% recurrence
- Side effects:
  - KeratoconjunctivitisRedness, itching, tearing, pain
  - ► Corneal erosion, punctate staining
  - Hyperemia
  - Punctal stenosis
  - MUST place punctal plugs
     Limbal stem cell deficiency
- Poorly tolerated compared with others
- Compounded
- ▶ Moderate cost in US











































Iris Tumors
The Pigment Spectrum

Melanocytoma
Malignant melanoma



### Iris Nevus Transformation to Melanoma


- ▶ ~3% risk at 5 years
- ► A age young ≤40 years
- ▶ B blood (hyphema or microhyphema)
- C inferior clock hour location 4:00-9:00
- ▶ D diffuse configuration involving entire iris surface
- E ectropion uveae
- F feathery tumor margins



### Sector Iris Nevus

- ► Involves section of iris
- Extends from pupil to angle
- ▶ Typically 3-4 clock hours
- May be congenital
- May be variant of melanocytosis






Iris Tumors
The Pigment Spectrum

Melanocytoma
Malignant melanoma

Iris Tumors
The Pigment Spectrum

Melanocytoma
Malignant melanoma



Iris Tumors
The Pigment Spectrum


Melanocytoma
Malignant melanoma

Iris Tumors
The Pigment Spectrum

Melanocytoma

Malignant melanoma


### Iris Melanoma • 4% of all uveal melanoma • Pigmented or amelanotic • Circumscribed or diffuse • Dome-shaped or flat • Corectopia 45% • Ectropion uveae 24% • Angle seeding 28% • Hyphema 3% • EOE 3%




### ▶ Complete ophthalmic examination, including IOP check, gonioscopy, dilated funduscopic examination ▶ Sitt lamp and gonio photography ▶ UBM ▶ LFTs, lung and liver imaging

### Treatment


- ➤ Iridocyclectomy
  ➤ Small
  ➤ Well-circumscribed
  ➤ Preferably not in CB
  ➤ Radilation
  ➤ Most lesions
  ➤ Plaque
  ➤ Proton
  ➤ Gamma
  ➤ Enucleation
  ➤ Large
  ➤ Glaucoma
  ➤ Poor VA potential











### Prognosis ➤ Favorable compared with other uveal melanoma ➤ <10% metastasis at 10 years ➤ Biopsy can be done for cytogenetics












### Iris Hemangioma


- Usually sporadic
- ► Capillary can regress with time
- ▶ Cavernous can be solitary or microhemangiomatosis
- Recurrent hyphema
- ▶ Racemose hemangioma = AV malformation
- Iris varix appears blue
- ► FA can help with diagnosis
- Laser or excision for recurrent hyphema















### Iris IPE Cyst








### Iris Stromal Cyst


- Usually clear (unlike pigmented IPE cyst)
- Congenital usually found by age 10
- ► Acquired can be idiopathic or from trauma/surgery
- > Spontaneous rupture can cause uveitis
- ▶ Needle aspiration to collapse cyst





### Freckle, nevus, melanocytoma, melanoma, histocytic, vascular, cystic Multimodal imaging Surgical excision Radiation Conclusions: Iris Tumors Corticosteroids Individualized based on symptoms, location, size





Posterior
Segment
Tumors

Melanocytosis
Nevus

The Pigment
Spectrum

Malignant melanoma

Posterior
Segment
Tumors

Melanocytosis
Nevus


The Pigment
Spectrum

Malignant melanoma

### Ocular Melanocytosis

- Aka Nevus of Ota
- ▶ Sclera, Iris, Choroid need UBM to r/o CB MM
- ► Cutaneous involvement oculodermal melanocytosis
- ▶ 1 in 400 risk of uveal melanoma
- Risk for orbital and meningeal melanoma MRI brain and orbits





Posterior
Segment
Tumors

Melanocytosis

Nevus

The Pigment
Spectrum

Malignant melanoma

Posterior	Melanocytosis
Segment Tumors	Nevus
The Pigment Spectrum	Malignant melanoma

## Choroidal and Ciliary Body Nevus Most common benign primary intraocular tumor (except maybe Fuchs adenoma) - 8% of US white population 1 in 8,845 risk of transformation to melanoma Detected after puberty Pigmented or amelanotic Fitat or dome Mean age 60, diameter 5.5, thickness <2 mm Associated PED, drusen, RPE trough, CNV

### Choroidal Nevus Transformation to Melanoma Clinical Features ▶ <u>T</u>o ▶ <u>T</u>hickness > 2mm ▶ <u>F</u>ind ► Subretinal <u>F</u>luid ► <u>S</u>mall <u>Symptoms</u> (flash/floater) ▶ <u>O</u>cular Orange pigment ▶ <u>M</u>elanoma ▶ <u>M</u>argin < 3 mm from ON <u>U</u>sing <u>H</u>elpful <u>H</u>ints ▶ <u>U</u>ltrasound <u>H</u>ollow ► <u>H</u>alo ▶ <u>D</u>rusen


### 


▶ <u>Dl</u>a<u>M</u>eter > 5mm


<u>D</u>oing <u>IM</u>aging


### 

# Risk Increases with More Factors 1 Factor: 11%, 3-fold 2 Factors: 22%, 11-fold 3 Factors: 34%, 15-fold 4 Factors: 51%, 15-fold 5 Factors: 55%, 26-fold









Posterior
Segment
Tumors

Melanocytosis

Nevus

Melanocytosis

Mevus

Malignant melanoma

Posterior
Segment
Tumors

The Pigment
Spectrum


Melanocytosis
Nevus

Malignant melanoma


### Choroidal and Ciliary Body Melanoma • 6 per 1 million • Melanotic or amelanotic • Dome or mushroom-shaped (broke through Bruch's) • Rarely diffuse • CB hidden by iris until large • Sentinel vessel, EGE, lens subluxation, sector cataract • Rarely ring-shaped and diffuse • Hollow/low internal reflectivity by ultrasound • Double circulation sign by FA/ICG




# Workup Complete ophthalmic examination Fundus photography OCT US Sometimes MRI brain/orbits LFTs, lung and liver imaging









Posterior Segment Tumors

The Amelanotic

Vascular

Lymphoma

Retinoblastoma



### Treatment

- ➤ Observe if asymptomatic
- ► Can cause hyperopic shift
- Associated SRF can reduce VA
- ▶ PDT
- Radiotherapy if resistant



### Choroidal Hemangioma

- Diffuse type
- Children
- ▶ Associated with Sturge Weber Syndrome
- ▶ Typically ipsilateral to cutaneous port wine mark
- ► Tomato catsup fundus
- Diffuse choroidal thickening
- Serous retinal detachment
- ► Neovascular glaucoma



### **Treatment**

- Treat amblyopia
- Treat amblyopiaOral propranolol
- External beam radiotherapy
- ► Enucleation for blind, painful eye




### Retinal Hemangioblastoma

- Solitary without systemic disease
- Multiple associated with systemic Von Hippel Lindau
  - Autosomal dominant
  - ► Chromosome 3
    - ► Inactivation of tumor suppressor gene
  - Three tumors: Retinal/cerebellar hemangioblastoma, pheochromocytoma, renal cell carcinoma
    - Also pancreatic neuroendocrine tumor, endolymphatic sac tumor, cysts in pancreas, kidne genitourinary tract

▶ Red-pink tumor in peripheral retina or optic disc

Retinal Hemangioblastoma

- Exudation
- Traction
- ► Feeding artery and draining vein
- ► Leakage by FA
  - ▶ FA to discover additional smaller, subtle lesions
- ▶ Observe if asymptomatic
- Laser, cryotherapy, PDT, TTT, radiotherapy
- ▶ Corticosteroids to prevent exudative response
- Modest benefit of anti-VEGF



Posterior Segment Tumors The Amelanotic <u>Vascular</u>

Lymphoma

Retinoblastoma

Posterior Segment Tumors


The Amelanotic


Vascular

Lymphoma

Retinoblastoma

### Choroidal Lymphoma Typically non-Hodgkin B-cell Often unilateral Associated conjunctival and orbital involvement Hollow choroidal thickening by US Epibulbar mass Seasick by OCT Look for conjunctival salmon patch to biopsy Systemic lymphoma workup Systemic treatment (rituximab) Or local radiotherapy





Posterior Segment Tumors

The Amelanotic

Vascular

Lymphoma

Retinoblastoma





### Clinical appearance Small, translucent retinal lesion Large, white calcified mass with feeding artery, draining vein, and retinal detachment Advanced, extraocular orbital mass

## Enucleation • Unilateral, advanced disease • Optic nerve involvement • Fewer follow-up visits • No chemotherapy or radiation exposure



### Chemotherapy ➤ Systemic, intravenous chemotherapy ➤ Consolidate: cryotherapy, TIT ➤ Targeted intra-arterial chemotherapy ➤ Intravitreal chemotherapy OA Posterior Ciliary Chorold





### **Systemic Monitoring**

- ► Germline at risk for second cancers
- ▶ MUST have a pediatric oncologist
- ➤ Get MRI brain and orbits with and without contrast with fat suppression q6months until age 5
  - ▶ To monitor for pineoblastoma
- ▶ Germline needs to be counseled about in vitro fertilization and preimplantation diagnosis

Conclusions: Posterior Segment Tumors

- Melanocytosis, nevus, melanoma, vascular, lymphoma, retinoblastoma Multimodal imaging

- Chemotherapy Cryotherapy

### End of the Tour

- Eye tumors can be benign or malignant
- Treatment and prognosis individualized
- ► Can save vision or even save a life!

Lauren A. Dalvin, MD Mayo Clinic, Rochester, MN @LADalvinMD Dalvin.Lauren@mayo.edu